Buy & Sell Hewlett Packard Enterprise Co (HPE) – Hewlett Packard Enterprise Co Price Today
Aura AI Summary
Key Stats
- $40.08BMarket Cap
- TechnologySector
- -12.39%3M Drawdown
- $56.85BEnterprise Value
- 1.89%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 52 daysTypical Hold Time
Hewlett Packard Enterprise Co (HPE) is currently valued at a market capitalization of $40.08B, with an enterprise value of $56.85B. Over the past 52 weeks, Hewlett Packard Enterprise Co has traded between a low of $17.28 and a high of $31.34, highlighting its annual price range. Over the past three months, Hewlett Packard Enterprise Co has recorded a drawdown of -12.39%, reflecting recent price volatility. Hewlett Packard Enterprise Co offers a dividend yield of 1.89%, with the most recent dividend of $0.14 paid on 24 Mar 26. On average, investors hold Hewlett Packard Enterprise Co for approximately 52 days, indicating typical investor behavior on the platform.
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Most Recent News
NevGold upsizes financing to C$42M, advancing US antimony-gold project with near-term production plans.
NevGold Corp. has increased its brokered private placement financing from C$25 million to over C$42 million due to strong institutional demand. The Vancouver-based junior miner is developing the Limousine Butte gold-antimony project in Nevada, target...
Quantum Cyber secures exclusive drone tech license amid $55B US drone warfare budget boost
Quantum Cyber has secured an exclusive license for BP United's autonomous drone technology, including a sky defense platform capable of over 25 km range and fully autonomous operations. This move positions Quantum Cyber to capitalize on the Trump adm...
Corbus Pharmaceuticals to present at RBC and Jefferies healthcare conferences in May and June 2026
Corbus Pharmaceuticals Holdings, a clinical-stage biotech company focused on oncology and obesity therapies, announced CEO Yuval Cohen will present corporate updates and meet investors at two major healthcare conferences in New York: the RBC Capital ...